DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20204265

A case report: remdesivir effective in the treatment of severe category COVID-19

Hetal Pandya, Archit Jain, Pradeep Reddy, Aarsh Shah

Abstract


Since the first cases were reported in December 2019, infection with the severe acute respiratory corona virus 2 (SARS-CoV-2) has become a worldwide pandemic. COVID-19 the illness caused by SARS-CoV-2 is overwhelming health care systems globally. In the absence of a proven effective therapy, current management consists of supportive care, including invasive and noninvasive oxygen support and off-label or compassionate-use therapies, including   anti-retrovirals, anti-parasitic agents, anti-inflammatory compounds, and convalescent plasma. Amongst these experimental therapies, remdesivir a broad-spectrum antiviral drug has shown some promising results. We present a successfully treated patient of severe acute respiratory illness by SARS-CoV-2 with remdesivir along with standard management protocol. Reporting a case with aim to add favoring evidence for remdesivir in the treatment of         SARS-CoV-2.


Keywords


Remdesivir, COVID-19, SARS-CoV-2

Full Text:

PDF

References


MK Sen N. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monal Archi Chest Dise. 2020;90(1294):193-96.

World health organization. Publications, Overview, Clinical management of COVID-19. Available at: WHO/2019-nCoV/clinical/2020.5. Accessed on 05 July 2020.

Sodani P, Mucci L, Girolimetti R, Tedesco S, Monaco F, Campanozzi D, et al. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. Respirat Med Case Rep. 2020;31:101115.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Resea. 2020;30(3):269-71.

Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biologic Chem. 2020;295(15),4773-9.

Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown A, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Natu Communic. 2020;11(1),222.

Hendaus MA. Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary. J Biomolec Struct Dynam. 2020;1-10.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Englnd J Med. 2020;382(24):2327-36.